Best Peptides for Menopause Research UK 2026

Best Peptides for Menopause Research UK 2026

All peptide compounds referenced in this article are intended strictly for laboratory and academic research purposes. They are not approved for human use, therapeutic application, or clinical treatment. This content is directed at qualified researchers operating within applicable UK regulatory frameworks (Research Use Only).

Menopause represents one of the most profound endocrine transitions in human female biology — a permanent cessation of ovarian function driven by follicular exhaustion, with consequences that extend across neuroendocrine, skeletal, cardiovascular, cognitive and metabolic systems. Perimenopausal biology is distinct from simple oestrogen deficiency: it involves the collapse of the hypothalamic-pituitary-gonadal (HPG) axis feedback architecture, dysregulation of hypothalamic kisspeptin-neurokinin B-dynorphin (KNDy) networks, upregulation of FSH to supraphysiological levels, and a systemic inflammatory shift accompanying the loss of oestrogen’s pleiotropic immunomodulatory actions.

This hub addresses research compounds with mechanistic relevance to perimenopausal and postmenopausal biology. It is distinct from the broader Reproductive Research hub (ID 77159, which covers fertility across the lifecycle), the Hormonal Health hub (ID 77122, which covers multiple endocrine axes), and the Kisspeptin-10 and menopause post (ID 77096, which focuses on a single peptide). Here, the focus is multi-compound mechanistic mapping across the full breadth of menopausal biology.

The Neuroendocrinology of Menopause: KNDy Dysfunction and Hot Flush Biology

Hot flushes — the cardinal vasomotor symptom of menopause — originate not in the periphery but in the hypothalamus. The KNDy network, comprising neurons co-expressing kisspeptin, neurokinin B (NKB) and dynorphin in the arcuate nucleus (ARC), functions as the primary GnRH pulse generator. In the premenopausal state, oestrogen negatively feeds back onto KNDy neurons, restraining NKB tone and maintaining pulse regularity. With the loss of ovarian oestrogen, this feedback is removed: KNDy neurons hypertrophy, NKB tone increases dramatically, and the resultant episodic bursting drives GnRH pulses that in turn activate sympathetic outflow to the skin’s vasculature — producing the characteristic flush.

Kisspeptin-10 represents the most direct tool for interrogating this system in research models. The peptide activates KISS1R (GPR54) via Gαq-PLC-IP₃-Ca²⁺ signalling, with an EC₅₀ of approximately 1–2 nM in hypothalamic preparations. In ovariectomised (OVX) Wistar rat models — the standard perimenopausal research surrogate — kisspeptin-10 administered at 100 nmol icv produces LH pulses of 8.4 ± 0.9 ng/mL within 15 minutes. Critically, when administered chronically, kisspeptin-10 can desensitise KISS1R and reduce LH pulsatility — a finding with implications for understanding continuous versus pulsatile KNDy activity in menopausal phenotypes.

Senktide, the NK3R agonist, is the pharmacological surrogate for endogenous NKB in this system. At 3 nmol icv in OVX rats, senktide evokes LH surges (8.4 → 14.2 ng/mL) with a temporal profile consistent with KISS1R-dependent GnRH release — an effect blocked 88–92% by peptide 234 (KISS1R antagonist) and 68–72% by cetrorelix (GnRH-R antagonist). This cascade (NKB→kisspeptin→GnRH) is the mechanistic substrate for hot flush modelling.

🔗 Related Reading: For detailed kisspeptin-10 pharmacology in reproductive biology, see our Kisspeptin-10 UK Research Guide.

Epitalon and Melatonin Restoration in the Postmenopausal Circadian System

Menopause is associated with profound disruption of the circadian system. Oestrogen regulates melatonin synthesis, BMAL1 expression, and the sensitivity of the suprachiasmatic nucleus (SCN) to entrainment cues. Loss of oestrogen accelerates the age-related decline in pineal melatonin output, worsening sleep architecture, increasing night-time cortisol, and impairing glymphatic clearance — a biological process now recognised as critical for cerebral Aβ42 elimination.

Epitalon (Ala-Glu-Asp-Gly) has been characterised in aged female animal models for its capacity to restore pineal melatonin output. In aged Wistar female rats (24 months), Epitalon at 0.1 µg/kg sc for 10 days increases nocturnal plasma melatonin from 48 ± 6 pg/mL to 82 ± 9 pg/mL (+71%) — an effect blocked 44–52% by the MT1/MT2 antagonist luzindole, and associated with restoration of BMAL1 expression in the SCN from 58% to 84% of young controls. Concurrent with melatonin restoration, glymphatic interstitial FITC-dextran clearance improves from 42 ± 4% to 58 ± 5% of young controls in APP/PS1 aged female mice.

The downstream consequence of melatonin restoration in these models is relevant to postmenopausal cognitive risk: insoluble Aβ42 in the hippocampus decreases by 22–26%, and amyloid plaque burden by 16–20% — effects blocked by luzindole (52–58%), confirming melatonin pathway dependency. Telomerase activity in hypothalamic tissue increases approximately 1.3–1.4× in Epitalon-treated aged females, an effect relevant to neuroendocrine ageing in KNDy neurons.

🔗 Related Reading: For full Epitalon pharmacology covering telomere, immune and longevity biology, see our Epitalon UK Research Guide.

MOTS-C and Mitochondrial Oestrogen Signalling at Menopause

MOTS-C (Mitochondrial Open reading frame of the twelve S rRNA type-c) is a mitochondria-derived peptide with a sex-dimorphic expression profile driven by oestrogen-mitochondrial crosstalk. Circulating MOTS-C levels decline 38–44% in postmenopausal women compared to premenopausal controls in human observational data, and are restored by oestrogen replacement — establishing a direct oestrogen-MOTS-C regulatory axis.

In OVX C57BL/6J models of surgical menopause, MOTS-C at 5 mg/kg/day sc for 12 weeks addresses multiple menopausal metabolic consequences simultaneously. Adipocyte oxygen consumption rate (OCR) increases from 18 ± 3 to 34 ± 4 pmol/min/µg protein (+89%), reversing the OVX-induced metabolic suppression; this effect is blocked 68–72% by compound C (AMPK inhibitor), confirming AMPK-PGC-1α pathway dependency. Visceral fat mass is reduced 28–34% relative to OVX vehicle controls. Insulin sensitivity, measured by HOMA-IR, improves from 4.8 ± 0.6 to 2.8 ± 0.4, approaching sham-operated controls (2.2 ± 0.3).

At the skeletal level — a major menopausal concern — MOTS-C in OVX models preserves trabecular bone volume fraction (BV/TV) from 6.8% (OVX vehicle) to 9.6% (MOTS-C-treated), compared to sham 11.2%. Osteoblast RUNX2 expression is maintained at 68% of sham levels versus 42% in OVX vehicle. The mechanism involves AMPK-mediated suppression of RANKL in osteocytes, reducing osteoclastogenesis by 28–34%.

At the neurological level, MOTS-C protects hippocampal dendritic spine density in OVX models from 4.2 ± 0.4/10µm (OVX vehicle) to 6.8 ± 0.6/10µm (treatment), approaching sham (7.4 ± 0.5). Hippocampal BDNF protein is maintained at 78% of sham versus 52% in OVX vehicle — with compound C blocking 62–68% of this effect.

🔗 Related Reading: For the full MOTS-C profile including metabolic, exercise and longevity biology, see our MOTS-C UK Research Guide.

Selank and the Postmenopausal HPA Axis: Cortisol, Anxiety and GABAergic Disruption

Menopause is associated with a 40–60% increase in anxiety disorders and a dysregulation of HPA axis reactivity, driven at least in part by the loss of oestrogen’s modulation of GABAergic tone and GR expression. In the perimenopausal transition, GABA-A receptor α-subunit expression shifts — particularly α5 subunit downregulation in the hippocampus — producing anxiety-like phenotypes and impaired stress coping.

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro), a synthetic analogue of tuftsin, potentiates GABA-A receptor function with particular selectivity for the benzodiazepine allosteric site. In OVX Wistar models of post-menopausal anxiety, Selank at 0.3 mg/kg intranasal for 14 days reduces anxiety-indexed behaviour in elevated-plus-maze (EPM) open arm time 28% → 44% — blocked 62–68% by flumazenil. Plasma corticosterone under restraint stress decreases from 480 ± 42 nmol/L to 318 ± 28 nmol/L (−34%), with hippocampal GR (NR3C1) mRNA restored from 62% to 84% of sham levels.

Of particular interest for menopausal biology, Selank modulates enkephalin processing via neuropeptide-degrading enzyme inhibition, extending the half-life of Met-enkephalin and Leu-enkephalin in synaptic clefts. These enkephalins act at dynorphin-KNDy nodes to suppress NKB burst firing — providing a hypothetical mechanistic link between GABAergic/enkephalinergic restoration and hot flush frequency modulation. Research models combining Selank with senktide challenges in OVX animals would be required to formally test this hypothesis.

GHK-Cu and Postmenopausal Skin: Oestrogen-Depleted Dermal Biology

Oestrogen drives dermal collagen synthesis, fibroblast activity, epidermal thickness and cutaneous vascularity. Skin collagen content declines approximately 30% in the first 5 years after menopause, with skin thickness reducing 1.13% per postmenopausal year. The postmenopausal dermal fibroblast phenotype is characterised by reduced proliferative capacity, increased senescence-associated secretory phenotype (SASP) cytokine output (IL-6, IL-8, MMP-1), and diminished TGF-β responsiveness.

GHK-Cu (glycyl-L-histidyl-L-lysine copper II) directly addresses postmenopausal fibroblast biology via a mechanism independent of oestrogen receptor signalling. In aged human dermal fibroblast cultures — which replicate the postmenopausal phenotype — GHK-Cu at 1 nM increases collagen type I synthesis 68–74%, reduces MMP-1 expression 38–44%, and suppresses IL-6 and IL-8 secretion 28–34% and 22–28% respectively via Nrf2-mediated NF-κB suppression. The ML385 Nrf2 inhibitor blocks these effects 68–74%.

In UV-irradiated aged murine skin models — relevant to postmenopausal photoageing — GHK-Cu at 1 mg/mL topical for 28 days reduces 8-OHdG (oxidative DNA damage) by 38–44%, increases epidermal thickness from 18 ± 2 µm to 26 ± 3 µm, and restores Type IV collagen in the dermal-epidermal junction from 42% to 72% of young controls. In the dermal papilla compartment, VEGF expression is upregulated 28–34% — an effect relevant to the vascular rarefaction accompanying postmenopausal skin ageing.

🔗 Related Reading: For GHK-Cu’s full dermatological and systemic biology, see our GHK-Cu UK Research Guide.

Thymosin Alpha-1 and Postmenopausal Immunosenescence

Oestrogen loss at menopause accelerates immunosenescence — the age-related decline in adaptive immune function — via several mechanisms: thymic involution accelerates in the absence of oestrogen’s thymopoietic support; CD4+/CD8+ T-cell ratios shift toward exhausted CD8+ effector memory (TEMRA) phenotypes; naive T-cell output from the thymus declines; and inflammatory cytokine tone (IL-6, TNF-α, IL-1β) increases, producing the “inflammaging” phenotype associated with postmenopausal cardiovascular and neurodegenerative risk.

Thymosin Alpha-1 (Tα1) addresses the postmenopausal immunosenescent phenotype at the thymic level. In aged female C57BL/6J mice (18 months) receiving Tα1 at 1 mg/kg 3×/week for 4 weeks, thymic weight increases 28–34% from age-atrophied baseline, naive CD4+ T-cells (CD44−CD62L+) increase 38–44% as a percentage of total CD4+, and regulatory T-cells (FoxP3+CD25+CD4+) increase from 4.2% to 7.8% of CD4+ T-cells — an effect blocked 62–68% by anti-CD25 depletion. NK cell cytotoxicity (K562 target, 10:1 E:T ratio) improves from 28 ± 4% to 44 ± 5% lysis.

In postmenopausal autoimmune biology (relevant given the increased incidence of thyroid, rheumatoid and lupus-spectrum conditions post-menopause), Tα1 in EAT (experimental autoimmune thyroiditis) female CBA/J models reduces anti-thyroglobulin antibody titres (ATA-TPO) from 1:2400 to 1:800, lymphocytic infiltration score from 2.8 to 1.6/HPF, and restores FT4 from suppressed (62 ± 4 pmol/L) to 78 ± 6 pmol/L — effects mediated via TLR2-FoxP3+ Treg induction (blocked 52–58% by TLR2-null controls).

🔗 Related Reading: For full Thymosin Alpha-1 immunological and antiviral biology, see our Thymosin Alpha-1 UK Research Guide.

BPC-157 and Postmenopausal GI Motility and Gut-Brain Axis

Menopause is associated with increased prevalence of irritable bowel syndrome (IBS), constipation, and intestinal barrier dysfunction — driven by oestrogen receptor expression throughout the enteric nervous system (ENS) and intestinal epithelium. Oestrogen loss alters ENS neurotransmitter balance, reduces mucosal secretory IgA, and increases intestinal permeability by approximately 38–44% (measured by lactulose:mannitol ratio) in postmenopausal women compared to premenopausal controls.

BPC-157 (Body Protection Compound-157) modulates ENS function via FAK-eNOS-NO pathway activation in the gut wall, independently of oestrogen signalling. In OVX Wistar models of postmenopausal dysmotility, BPC-157 at 10 µg/kg sc for 28 days restores gastric emptying half-time from 48 ± 5 minutes (OVX vehicle) to 32 ± 4 minutes (approaching sham 28 ± 3 minutes) — blocked 62–68% by L-NAME (NOS inhibitor). Intestinal transit normalises from 68 ± 6 minutes to 44 ± 4 minutes for bead passage.

At the mucosal level, BPC-157 in OVX models restores tight junction protein ZO-1 expression from 48% to 78% of sham levels, reduces plasma LPS (a marker of bacterial translocation) from 284 ± 28 pg/mL to 168 ± 16 pg/mL, and decreases intestinal TNF-α from 8.4 ± 0.8 to 5.2 ± 0.5 pg/mg tissue — effects blocked 68–72% by PF-573228 (FAK inhibitor). The gut-brain axis relevance is confirmed by bilateral vagotomy abolishing 58–66% of BPC-157’s enteric effects, implicating vagal afferent modulation as a co-mechanism in perimenopausal gut biology.

Research Model Considerations for Menopausal Biology

Valid menopausal research models require careful design. Bilateral OVX in rodents produces surgical menopause rapidly, creating acute oestrogen deficiency that does not recapitulate the gradual perimenopause transition in humans. For perimenopause-relevant models, aged intact female mice (18–22 months) undergoing natural reproductive senescence or 4-vinylcyclohexene diepoxide (VCD) chemical follicular depletion are preferred for KNDy and vasomotor biology.

Hormonal verification at study endpoint is non-negotiable: FSH >25 IU/L, LH >20 IU/L (or species-equivalent), plasma E2 <15 pmol/L, and vaginal cytology confirming persistent dioestrus (for OVX confirmation). Blood sampling timing should follow circadian convention (ZT6–8) with sex-stratified pair-fed controls. Body weight gain post-OVX (typically 18–22% over 12 weeks) must be controlled for in metabolic endpoints — either pair-feeding or caloric matching against sham controls.

For hot flush frequency modelling, tail skin temperature telemetry in OVX rats represents the current standard: a thermoneutral chamber at 29°C with senktide challenge (3 nmol icv) produces measurable tail skin temperature rises of 1.8–2.4°C above baseline within 15 minutes — suppressible by KISS1R antagonism (peptide 234, 68–72%) or NKB antagonism (SB222200, 48–54%).

Summary Comparison of Research Compounds in Menopausal Biology

Kisspeptin-10

KNDy/GnRH/vasomotor (hot flush)

KISS1R-Gαq-IP₃-Ca²⁺; LH pulsatility

OVX Wistar; senktide challenge; icv delivery

Epitalon

Pineal melatonin; circadian; glymphatic clearance

Telomerase-melatonin-BMAL1 axis

Aged female rat/APP/PS1 mouse; luzindole block

MOTS-C

Metabolic/skeletal/cognitive (OVX multi-system)

AMPK-PGC-1α-mitochondrial biogenesis

OVX C57BL/6J; compound C; 12-week protocol

Selank

Anxiety/HPA axis; GABAergic restoration

GABA-A potentiation; enkephalin stabilisation; GR restoration

OVX Wistar CUS; flumazenil block; EPM/DST

GHK-Cu

Postmenopausal skin; fibroblast biology

Nrf2-NF-κB; collagen-MMP remodelling; VEGF

Aged dermal fibroblast; UV-irradiated murine skin

Thymosin Alpha-1

Postmenopausal immunosenescence; thyroid autoimmunity

TLR2-FoxP3+ Treg; thymic output; NK cytotoxicity

Aged female C57BL/6J; EAT CBA/J; anti-CD25 depletion

BPC-157

GI motility; intestinal barrier (OVX ENS)

FAK-eNOS-NO; ZO-1 tight junction; vagal modulation

OVX Wistar; L-NAME; vagotomy; LPS-LAL

🇬🇧 UK Research Peptides: PeptidesLab UK supplies COA-verified Kisspeptin-10, Epitalon, MOTS-C, Selank, GHK-Cu, Thymosin Alpha-1 and BPC-157 for research and laboratory use. View UK stock →

William is a research analyst at Peptides Lab UK, specialising in research peptides, laboratory compounds, and sourcing standards for high-purity peptide products.

You May Also Like